{"id":51077,"date":"2022-11-21T15:02:02","date_gmt":"2022-11-21T14:02:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/"},"modified":"2022-11-21T15:02:02","modified_gmt":"2022-11-21T14:02:02","slug":"swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/","title":{"rendered":"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment"},"content":{"rendered":"
\n

\nAbstracts presented at the American College of Rheumatology (ACR) annual meeting demonstrate exciting results for digital therapeutics<\/i>\n<\/p>\n

\nSwing Care launches in Texas to focus on virtual treatment of fibromyalgia patients<\/i>\n<\/p>\n

SAN FRANCISCO–(BUSINESS WIRE)–Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, today announced the presentation of research supporting the use of its digital therapeutic to deliver behavioral therapy for fibromyalgia management. Swing Therapeutics reported early results from a prospective single-arm clinical trial (REACT-FM), which were presented at the American College of Rheumatology (ACR) annual meeting last week.\n<\/p>\n

<\/a><\/p>\n

\nSwing Therapeutics has developed Stanza<\/a>, a prescription smartphone-based digital therapeutic for fibromyalgia management. The core of the treatment is acceptance and commitment therapy (ACT), a type of cognitive behavioral therapy (CBT) with proven efficacy in treating fibromyalgia. Stanza is designed to help adult patients manage the psychological symptoms associated with fibromyalgia, including anxiety, depression, and sleeplessness. It was made available to patients in September 2022 under the FDA\u2019s Digital Health Enforcement Policy for Digital Health Devices, and is available by prescription via a healthcare provider.\n<\/p>\n

\n\u201cThis real-world data expands the growing body of clinical evidence supporting the use of digital therapeutics for the management of fibromyalgia, and reinforces the positive outcomes observed from a previous randomized controlled trial<\/a>,\u201d said Mike Rosenbluth, Ph.D., founder and CEO of Swing Therapeutics. \u201cAs we gather additional compelling evidence, our mission is to make digital behavioral therapeutics like Stanza become more accessible to people with fibromyalgia. The launch of Swing Care is an exciting step toward broadening the reach of telemedicine and digital health to a wider population of patients.\u201d\n<\/p>\n

\nSwing Care<\/a>, an online clinic focused specifically on the treatment of fibromyalgia, launched in Texas in 2022 to focus on holistic treatment for fibromyalgia patients, and includes digital therapeutics as a care option.\n<\/p>\n

\n\u201cPeople living with fibromyalgia often fall through the cracks of healthcare, and better solutions are needed to improve the quality of their lives. This clinical data demonstrates the power of digital behavioral therapeutics to make a meaningful difference. Swing Care has partnered with Swing Therapeutics to expand access through telehealth to specialized, clinically proven fibromyalgia treatment that otherwise has only been available from a limited number of providers,\u201d said Andrea Chadwick, M.D., a globally recognized expert on the treatment of fibromyalgia and Medical Director of Swing Care. \u201cWith Swing Care, patients will receive personalized treatment plans that meet their unique needs, including access to behavioral therapies like Stanza and medication management as needed.\u201d\n<\/p>\n

\nClinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management in a Decentralized Trial<\/b>\n<\/p>\n

\nIn this study, participants were primarily evaluated using the Patient Global Impression of Change (PGIC) Scale. Other outcomes collected include the Revised Fibromyalgia Impact Questionnaire (FIQ-R), as well as instruments that measure pain intensity and interference, sleep interference, depression, anxiety, pain acceptance, mindfulness, and quality of life (QoL). Outcomes were measured after 12 weeks of using the app, and then analyzed against baseline scores for all completed participants.\n<\/p>\n

\nAt the end of the course of a 12-week therapy, participants with fibromyalgia achieved improvement in all areas measured. Eighty-four percent of participants reported improvement in their fibromyalgia condition after Stanza treatment, with 47 percent reporting to be \u201cmuch\u201d or \u201cvery much\u201d improved.\n<\/p>\n

\n\u201cPeople with fibromyalgia have no cure for their condition, and often have trouble managing symptoms, including pain, brain fog, sleep disturbances and anxiety and depression,\u201d said Yifei Dai, Ph.D., Head of Clinical and Scientific Affairs at Swing Therapeutics. \u201cI\u2019m encouraged by the results we saw from patients throughout the study and look forward to gathering additional evidence.\u201d\n<\/p>\n

\nThe full publication can be accessed at: https:\/\/acrabstracts.org\/abstract\/clinical-impact-of-a-digital-behavioral-therapy-for-fibromyalgia-management-in-a-decentralized-trial\/<\/a>\n<\/p>\n

\nUsability and Acceptability of a Digital Behavioral Therapy for the Management of Fibromyalgia<\/b>\n<\/p>\n

\nSwing Therapeutics also reported results of usability research on Stanza that was conducted as part of the REACT-FM trial. <\/b>In this study, participants evaluated Stanza\u2019s ease of use, interface, and overall satisfaction via the mHealth App Usability Questionnaire (MAUQ) at the end of the 12-week treatment. Treatment preference for the digital therapeutic application versus medication management was evaluated for participants who currently or previously used FDA-approved pharmacological treatments for fibromyalgia.\n<\/p>\n

\nAt the end of the 12-week program, 84 percent and 88 percent of participants reported positive ratings in the MAUQ domains of \u2018Ease of Use\u2019 and \u2018Interface and Satisfaction\u2019, respectively. Approximately 90 percent of participants who had used FDA-approved fibromyalgia medications preferred treatment with Stanza, or Stanza combined with approved fibromyalgia medication, versus treatment with approved medication alone.\n<\/p>\n

\n\u201cOther self-guided digital behavioral therapies on the market have been created to address accessibility and scalability issues, but many have low engagement due to poor usability,\u201d said Nelson Mitchell, Head of Product at Swing Therapeutics. \u201cWe\u2019re encouraged by the positive results from this study that support our therapy\u2019s usability and satisfaction for fibromyalgia management.\u201d\n<\/p>\n

\nThe full publication can be accessed at: https:\/\/acrabstracts.org\/abstract\/usability-and-acceptability-of-a-digital-behavioral-therapy-for-the-management-of-fibromyalgia\/<\/a>\n<\/p>\n

\nAbout Fibromyalgia<\/b>\n<\/p>\n

\nFibromyalgia is a chronic and debilitating pain condition that affects an estimated 10 million Americans. The condition is characterized by widespread pain and other physical and cognitive symptoms that include fatigue, disrupted sleep, reduced physical function, memory problems and difficulty concentrating (\u201cbrain fog\u201d), and is often accompanied by anxiety and depression. Because fibromyalgia manifests differently across the affected patient population and can be masked by other accompanying conditions, it is difficult to diagnose and treat.\n<\/p>\n

\nAbout Swing Therapeutics<\/b>\n<\/p>\n

\nSwing Therapeutics was founded in 2019 with the goal of developing digital treatments and services in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development of prescription-based digital therapies and services. Swing Therapeutics received FDA Breakthrough Device Designation for its digital therapy for fibromyalgia management. Its near-term goal is to validate its digital therapy and bring it to market as an FDA-cleared, prescription digital therapeutic. For more information visit swingtherapeutics.com<\/a>.\n<\/p>\n

\nAbout Swing Care<\/b>\n<\/p>\n

\nSwing Care was founded in 2022 to increase access to evidenced-based, holistic treatment for patients living with fibromyalgia. The virtual clinic is focused specifically on the treatment of fibromyalgia and launched with licensed providers in Texas. Clinical protocols were developed by Medical Director Dr. Andrea Chadwick, a globally recognized expert in fibromyalgia care. For more information visit swing.care<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSarah Lundberg
\n
Health+Commerce
\n
612.770.0359
\n
sarahlundberg@healthandcommerce.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Abstracts presented at the American College of Rheumatology (ACR) annual meeting demonstrate exciting results for digital therapeutics Swing Care launches in Texas to focus on virtual treatment of fibromyalgia patients SAN FRANCISCO–(BUSINESS WIRE)–Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, today announced the presentation of research supporting the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51077","6":"format-standard","7":"category-industry"},"yoast_head":"\nSwing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Abstracts presented at the American College of Rheumatology (ACR) annual meeting demonstrate exciting results for digital therapeutics Swing Care launches in Texas to focus on virtual treatment of fibromyalgia patients SAN FRANCISCO–(BUSINESS WIRE)–Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, today announced the presentation of research supporting the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T14:02:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221121005171\/en\/1643294\/21\/Swing_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment\",\"datePublished\":\"2022-11-21T14:02:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/\"},\"wordCount\":1089,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005171\\\/en\\\/1643294\\\/21\\\/Swing_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/\",\"name\":\"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005171\\\/en\\\/1643294\\\/21\\\/Swing_logo.jpg\",\"datePublished\":\"2022-11-21T14:02:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005171\\\/en\\\/1643294\\\/21\\\/Swing_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005171\\\/en\\\/1643294\\\/21\\\/Swing_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment - Pharma Trend","og_description":"Abstracts presented at the American College of Rheumatology (ACR) annual meeting demonstrate exciting results for digital therapeutics Swing Care launches in Texas to focus on virtual treatment of fibromyalgia patients SAN FRANCISCO–(BUSINESS WIRE)–Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, today announced the presentation of research supporting the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-21T14:02:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221121005171\/en\/1643294\/21\/Swing_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment","datePublished":"2022-11-21T14:02:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/"},"wordCount":1089,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221121005171\/en\/1643294\/21\/Swing_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/","url":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/","name":"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221121005171\/en\/1643294\/21\/Swing_logo.jpg","datePublished":"2022-11-21T14:02:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221121005171\/en\/1643294\/21\/Swing_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221121005171\/en\/1643294\/21\/Swing_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/swing-therapeutics-announces-positive-results-from-studies-of-stanza-a-digital-therapeutic-for-fibromyalgia-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51077"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51077\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}